Results of botilinum toxin: An application to blepharospasm in Schwartz-Jampel syndrome

Basit Öğe Kaydı
dc.contributor.authorVargel, İbrahim
dc.contributor.authorCanter, Halil İbrahim
dc.contributor.authorTopaloglu, Haluk
dc.contributor.authorErk, Yücel
dc.date.accessioned2020-06-25T17:43:31Z
dc.date.available2020-06-25T17:43:31Z
dc.date.issued2006
dc.description.abstractSchwartz-Jampel syndrome (SJS) is a rare congenital disorder of continuous myotonia, causing visual and eyelid problems such as blepharospasm, acquired ptosis, and blepharophimosis. We report the management of blepharospasm in two sisters with Schwartz-Jampel syndrome with application of botilinum toxin type A (BTX-A), as an alternative to the surgical treatments, such as orbicularis oculi myectomy, levator aponeurosis resection, and lateral canthopexy as described in the literature. Three consequent doses of commercially available BTX-A (Botox(R)-Allergan, Inc. 100 u/via) were injected to orbicularis oculi muscle in two sisters with Schwartz-Jampel syndrome. At the least, the authors waited for a six-month interval to prevent development of sensitivity to BTX-A in patients. No significant improvement was observed after the injection of first dose of BTX-A, with the total dose of 25 units of BTX-A to each orbicularis oculi muscle of the eyes. The muscle tone weakened after the second dose, which was the twice as such of the first applied total dose (50 units of BTX-A to each orbicularis oculi muscle of the eyes) and significant functional and cosmetic improvements were achieved after injection of the third dose, in which the total applied dose was the same as the one applied in second dose. The blepharospasm and eyelid alterations caused by Schwartz-Jampel syndrome should be treated to provide functional and cosmetic improvements. Application of BTX-A to orbicularis oculi muscle for the treatment of blepharospasm could be considered as an alternative to levator resection, and lateral canthopexy in Schwartz-Jampel syndrome.en_US
dc.identifier.citationclosedAccessen_US
dc.identifier.doi10.1097/00001665-200607000-00008
dc.identifier.endpage660en_US
dc.identifier.issn1049-2275
dc.identifier.issue4en_US
dc.identifier.pmid16877909
dc.identifier.scopus2-s2.0-33746803756
dc.identifier.scopusqualityQ3
dc.identifier.startpage656en_US
dc.identifier.urihttps://doi.org10.1097/00001665-200607000-00008
dc.identifier.urihttps://hdl.handle.net/20.500.12587/3754
dc.identifier.volume17en_US
dc.identifier.wosWOS:000239535700008
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherLippincott Williams & Wilkinsen_US
dc.relation.ispartofJournal Of Craniofacial Surgery
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectblepharospasmen_US
dc.subjectbotilinum toxin type A (BTX-A)en_US
dc.subjectSchwartz-Jampel syndromeen_US
dc.titleResults of botilinum toxin: An application to blepharospasm in Schwartz-Jampel syndromeen_US
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
Results of botilinum toxin An application to blepharospasm in Schwartz-Jampel syndrome.pdf
Boyut:
202.3 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin/Full Text
İndir

Koleksiyon

WOS İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu